title: Systematic evaluation of dose accumulation studies in clinical pharmacokinetics.
abstract: The amount of drug remaining after previous doses, or drug accumulation, is closely related to drug efficacy and safety. An accurate calculation of the accumulation index or ratio (R(ac)) is crucial for dose finding. However, in drug accumulation studies little consensus exists with regard to experimental design or data analysis. We conducted a systematic review of the literature to produce a detailed profile of drug accumulation studies of the last 30 years (1980-2011). Ninety-six articles comprising 122 studies were analyzed. A typical drug accumulation study enrolled 10 to 20 subjects randomly assigned into treatment groups of 1 or 2 dose levels to observe pharmacokinetic behaviors. The median washout period between single and multiple dosing was 7 days, and the dose interval was 1-2 elimination half-lives in non- or one-compartmental models. Generally, the number of repeated times of administration for multiple dosing was 7-14, and the median number of sampling time points was 11. Eight different methods were used to calculate R(ac). The most frequently used method, in 72.9% of the studies, was to set R(ac) equal to the ratio of the area under a plasma concentration-time curve (AUC) during a dosage interval at steady state to the AUC of a dosage interval after the first dose, i.e., R(ac) = AUC(0-τ,ss) / AUC(0-τ,1). The values of R(ac) in the included studies ranged from 0.85 to 18.8, and 68.03% were <2. We suggest that sample size estimation for an accumulation study should be similar to that of a bioequivalence study, and in most studies, 18-24 subjects will be needed. Appropriate calculation methods for R(ac) should be selected based on the experimental design and data characteristics. The crucial values for non-, weak, moderate, and strong accumulation can be set at R(ac) < 1.2, 1.2 ≤ R(ac) < 2, 2 ≤ R(ac) < 5, and R(ac) ≥ 5, respectively. Accumulations studies should also give more regard to drug metabolism and increased accumulation in kidney or liver damaged patients.
authors.affiliation: Center for Drug Clinical Research, Shanghai University of Chinese Medicine, Shanghai, P.R. China.
authors.forename: Lujin
authors.initials: L
authors.lastname: Li
authors.forename: Xianxing
authors.initials: X
authors.lastname: Li
authors.forename: Ling
authors.initials: L
authors.lastname: Xu
authors.forename: Yucheng
authors.initials: Y
authors.lastname: Sheng
authors.forename: Jihan
authors.initials: J
authors.lastname: Huang
authors.forename: Qingshan
authors.initials: Q
authors.lastname: Zheng
mesh_terms: D000818:Animals; D019540:Area Under Curve; D006207:Half-Life; D006801:Humans; D004364:Pharmaceutical Preparations / Q000008:administration & dosage* / Q000378:metabolism; D010599:Pharmacokinetics; D018401:Sample Size; D013997:Time Factors
chemical_list: D004364:Pharmaceutical Preparations